Journal Home
Search for

Volume 32, Issue 2, Pages 119-125 (March 2010)


View previous. 4 of 16 View next.

Can an accelerometer enhance the utility of the Timed Up & Go Test when evaluating patients with Parkinson's disease?

Aner Weissa, Talia Hermana, Meir Plotnika, Marina Brozgola, Inbal Maidana, Nir Giladiac, Tanya Gurevichac, Jeffrey M. HausdorffabdCorresponding Author Informationemail address

Received 31 March 2009; received in revised form 17 August 2009; accepted 26 October 2009. published online 27 November 2009.

Abstract 

Introduction

The Timed Up and Go (TUG) test is a widely used measure of mobility and fall risk in older adults and in Parkinson's disease (PD). We tested the hypothesis that body-fixed accelerometers can provide insight into TUG performance in PD patients.

Methods

We examined 17 patients with PD (Hoehn and Yahr score: 2.7±0.7; ON state) and 15 age-matched healthy controls; mean ages were 66.8±5.9 years, 67.6±9.6 years, respectively. Subjects wore a 3D-accelerometer (ADXL330, Analog Devices) on the lower back while performing the TUG test. Sit-to-Stand and Stand-to-Sit times were extracted from the anterior–posterior (AP) signal. Parameters included Sit-to-Stand, Stand-to-Sit durations, amplitude range (Range) and slopes (Jerk). Acceleration median and standard deviation (SD) were also calculated.

Results

Stopwatch-based TUG duration tended to be higher for the PD patients compared to the control group, although not significantly (p=0.08). In contrast, the TUG duration that was extracted from the acceleration signal was significantly (p<0.02) higher in the PD group compared to the control group. Many acceleration-parameters were also significantly different (p<0.05) between groups; most were not correlated with TUG duration.

Conclusions

Accelerometer-derived parameters are sensitive to group differences, indicating that PD patients have poorer mobility during specific aspects of the TUG. In addition to test duration, these measures may serve as complementary and objective bio-markers of PD to augment the evaluation of disease progression and the response to therapeutic interventions.

a Laboratory for Gait & Neurodynamics, Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

b Dept of Physical Therapy, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

c Dept of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

d Division on Aging, Harvard Medical School, Boston, MA, USA

Corresponding Author InformationCorresponding author at: Laboratory for Gait & Neurodynamics, Tel.: Aviv Sourasky Medical Center, 6 Weizman Street, Tel-Aviv 64239, Israel. Tel.: +972 36974958; fax: +972 36947514.

PII: S1350-4533(09)00231-8

doi:10.1016/j.medengphy.2009.10.015


View previous. 4 of 16 View next.